Putting outlook toward pre-CMS submission analytics to the test, qordata conducted a poll during its webinar earlier this month. The question was: “How important are analytics for reviewing spend prior to submission?”
The results were unsurprising: 63% of participants believed using analytics prior to CMS submission was “Very Important,” with another 31% saying it was “Important”. Only 6% were unsure of their choice. Significantly, no one said analytics were “Not Important”.
Why do so many Transparency and Compliance professionals believe every CMS Submission must be prefixed by a comprehensive run of spend data analytics?
Managed this way, data identifies its own potential for disputes. Pinpointing entries that suspiciously fall in the outlier category and it mitigates future disputes.
An aggregate spend reporting solution will help flag conflicting transactions with HCPs in the past, allowing users to probe as deeply as they wish: Users can conduct deep-dive analytics based on TOV, location, specialty, and even the drug for which the HCP was engaged.
With its necessity established, one must ask: Why aren’t all pharmaceutical drug and device manufacturers using analytics? Possibly worried about:
-
Cost
-
Time
-
Resources engaged in developing/running an in-house solution
-
Data security
-
Level of Expertise
At qordata, we continue to effectively allay our own clients’ concerns about these every day. In the coming weeks, we hope to address each in a dedicated blog.
If there are other concerns we haven’t covered, we’d really like to hear from you (especially that 6%)!
